GlassScriptPhysician profile
Divyesh G Mehta
NPI 1205949724
$413.68
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $113.07 | 2019 | |
| Janssen Biotech, INC. | $75.49 | 2019 | |
| Exelixis INC. | $32.18 | 2019 | |
| Lilly USA, LLC | $31.43 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.48 | 2019 | |
| Seagen INC. | $22.89 | 2019 | |
| Puma Biotechnology, INC. | $21.71 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $20.25 | 2019 | |
| Amgen INC. | $16.32 | 2019 | |
| Emmaus Medical, INC. | $16.11 | 2019 | |
| Gilead Sciences, INC. | $15.76 | 2019 | |
| Clovis Oncology, INC. | $12.57 | 2019 | |
| Astellas Pharma US INC | $12.42 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divyesh Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.